Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid Tumors

NCT05302921 is registered in ClinicalTrials.gov with Children's National Research Institute as lead sponsor.

NCT NCT05302921
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05302921 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Investigating the Efficacy of Neoadjuvant Dual Checkpoint Inhibition and Cryoablation Therapy in Children, Adolescents, and Young Adults With Relapsed/Refractory Solid Tumors
Lead sponsor
Children's National Research Institute
Phase
Phase 2
Overall status
Completed
Start date
February 18, 2022
Completion date
March 12, 2024
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ewing sarcoma, hepatoblastoma, hepatocellular carcinoma, melanoma, neuroblastoma, osteosarcoma, refractory pediatric solid tumor, relapsed pediatric solid tumor, rhabdomyosarcoma, wilms tumor